#Acute myeloid leukemia

[everythingelvispresley]

Hi everyone. I have been quiet on here. It's been a rough time the last 4 to 5 days. My uncle is receiving end of life care for AML, and it has affected my own health. He is hanging in as long as he can.

[bpod-bpod]

Vessels and Vesicles

Acute myeloid leukaemia (AML) is a type of blood cancer characterised by excessive production of abnormal white blood cells. The disease causes wide-spread inflammation and is especially damaging to blood vessels within the bone marrow where the leukaemic cells are produced. The video shows skull bone vasculature (green) of a healthy mouse and a mouse with AML (leukaemic cells coloured red) in which the vessels have been ravaged by the disease. Researchers have discovered that, as this vessel damage increases, so too does the circulating level of extracellular vesicles – small membranous packages derived from cells. Extracellular vesicles are produced from healthy vascular cells as a form of cell-to-cell communication. But, when the cells are stressed (as in the case of AML) vesicle production ramps up dramatically. Monitoring vesicle levels could therefore be used to assess the extent of vessel damage in AML and the success of a given treatment.

Written by Ruth Williams

Video from work by Georgia K. Atkin-Smith and colleagues

Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia

Video originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)

Published in Nature Communications, October 2024

You can also follow BPoD on Instagram, Twitter and Facebook

[jcsmicasereports]

Acute Myeloid Leukemia In Pregnancy: Difficult Journey From Diagnosis To Delivery And Treatment by Vina Kumari in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

The incidence of Acute Myeloid Leukemia in pregnancy is about 1 in 75,000 to 1 in 100,000. Owing to the therapy attributable risks to mother and fetus, the management of AML in pregnancy is very challenging, both for the parents and the medical fraternity. Furthermore, the diagnosis of leukemia in pregnancy is very difficult owing to vague presenting symptoms like fatigue and weakness which are confused with physiological changes during pregnancy.

Case Report: Primigravida, 33 weeks 6 days gestation age, with history of weakness and fatigue for 15 days and fever, cough and cold for 3 days was referred to our hospital with blood reports of raised total leucocyte count. The lab reports showed thrombocytopenia, anemia and leukocytosis with increased circulating blasts in the peripheral smear. As she was in her third trimester, plan of induction of labor and delivery followed by chemotherapy was taken. She delivered a live healthy baby. Post-delivery, she was advised chemotherapy. She had an immediate remission after the chemotherapy. The disease relapsed after 10 months and she succumbed to the disease due to unavailability of facilities during the COVID pandemic.

Conclusion: AML during pregnancy is rare. There is no fixed protocol for management of AML during pregnancy .The aim of management should be to take care of the initial concerns regarding fetal well-being according to gestation age and commence chemotherapy as soon as possible. This would give the best survival chances to the mother.

Keywords: Acute myeloid leukemia, pregnancy, chemotherapy.

Introduction

The association of leukemia and pregnancy is very rare, rather under-diagnosed and sparsely reported. The prevalence based on diagnosed and reported cases is one in 75,000 to 100,000 pregnancies. Most of the leukemias diagnosed in pregnancy are myeloblastic.

Acute myeloid leukemia (AML) is characterized by excessive proliferation of blast cells of myeloid lineage. This results in hematopoietic insufficiency like anemia and thrombocytopenia. The symptoms are related to complications of the pancytopenia, such as infections or hemorrhagic diathesis. The mentioned initial symptoms of leukemia in pregnancy are easily attributed to physiological changes related to the pregnancy and hence are either missed or diagnosed late. We report a case of Acute Myeloid Leukemia in a pregnant patient, its management and outcome.

Case Presentation

18-year-old primigravida presented at 33 weeks 6 days gestation. She was referred with history of weakness since 15 days and fever, cough, cold since 3 days associated with raised leucocyte count. She belonged to low socioeconomic status, was unbooked and had two antenatal visits during her pregnancy. She visited the facility when she had symptoms of gross weakness.

Her first trimester was uneventful. She was registered at a local hospital but was not compliant. Dating scan, trisomy screening and anomaly scan was not done.

On examination, her pulse rate was 88, blood pressure 100/60, respiratory rate 20 per minute, and temperature 99 degree Fahrenheit. She was pale but there was no jaundice, icterus or edema. She had angular stomatitis, and glossitis indicating malnutrition. Lymph nodes were not palpable.

On per abdomen examination, Uterus was relaxed, 33-34 weeks size and fetal heart 143/min. Ultrasound showed a single live fetus in cephalic presentation with effective fetal weight of 2.4 kg and liquor 12.7cm. Placenta was in upper posterior position. The fetus had overdistended urinary bladder with hydronephrosis of fetal kidneys suggestive of bladder outlet obstruction. Moderate hepatosplenomegaly was present. She was moderately anemic with hemoglobin of 8.3 gm/dl. The leucocyte count was very high 2,66,000/cu mm with neutrophils 4, lymphocytes 1, eosinophils 1 and basophils 1. The blood picture showed marked leucocytosis with blasts cells predominating 86% and 2 myelocytes and 1 metamyelocyte. The blast cells typically showed large nuclei, opened up chromatin, prominent nucleoli and cytoplasmic blebs. This picture raised the suspicion of Acute Myeloid Leukemia in pregnancy. Her platelet count was 96000/cu mm. LDH was raised 995 U/L signifying cell lysis. Liver enzymes were also borderline raised. Dengue serology was found negative. Her blood group was O negative. Serum Creatinine - 1.05 mg/dl and Serum uric acid - 10.9 mg/dl were also raised. The blood picture thus indicated towards normochromic normocytic anemia, thrombocytopenia and leukocytosis. On further examination of the peripheral blood smear, a leukoerythroblastic formula was noted with the presence of predominant blast population (86%).

Peripheral smear showed mostly Monoblasts (red arrow), promonocytes (green arrow) and few myeloblasts (blue arrow) under the oil immersion object 100 X, Leishman stain.

Monoblasts are large cells with abundant cytoplasm, moderately to intensely basophilic, scattered fine azurophilic granules, round nuclei with lacy chromatin and one or more large nucleoli.

Promonocytes have moderate cytoplasm, less basophilic, granulated with occasional large azurophilic granules. Vacuoles are more irregular. Nuclei are delicately folded.

Myeloblasts have large nuclei, fine chromatin, 3-4 prominent nucleoli and few Auer rods in the cytoplasm.

In view of suspected Acute Myeloid Leukemia, she was advised Bone marrow aspiration, biopsy and immunophenotyping, flow cytometry and translocation (15:17) study by oncologist.

The obstetrical examination was normal. All cardiotocographies were reactive. She was started on IV antibiotics, Inj Ceftriaxone 1 gm IV BD and steroids, Inj Betamethasone was given for fetal lung maturity. In view of malignancy with pregnancy, the case was discussed in tumor board on 10/9/19 and a decision for delivery followed by chemotherapy was taken.

She was induced with one dose of intracervical dinoprostone gel following which she went into labour and delivered live baby 2.8 kg weight with good apgar. The baby was shifted to nursery in view of premature delivery and mother was planned to transfer to medical oncology department for Induction chemotherapy.

Repeat investigations three days after delivery, haemoglobin decreased to 7 g/dl, TLC increased to 3,81,000 cells per cu mm with neutrophils 2, lymphocytes 5 and myelocytes 5. The abnormal blast cells had increased to 88% and platelets decreased to 21000 per cu mm (TABLE 1). Serum creatinine also increased to 1.43 mg/dl and e-GFR decreased to 54 ml/min/1.73 m2, indicating compromised renal function. The peripheral picture showed mostly agranuloblasts with moderate to scanty grey blue vacuolated cytoplasmic nuclei showing convolutions and 1-3 nucleoli occasional myelocytes, metamyelocytes seen, findings in favour of Acute myeloid leukemia (M4/M5). On myeloperoxidase staining, only 40 % took up the stain indicating AML-M4 lineage. She was transfused with one packed cell and one single donor platelet, following which her condition improved. She was transferred to medical oncology ward where she received chemotherapy and had immediate remission of the disease.

Discussion

The Incidence of Acute Myeloid Leukemia is 1 in 75,000 to 100,000 pregnancies with maximum 40% presenting in third trimester and 23% and 37% in first and second trimester respectively. In a population based study by Nolan et al [1], out of total acute leukaemia cases, two thirds are myeloblastic and one third lymphoblastic leukemia.

The rarity of disease during pregnancy, might also be due to very low reporting in view of confusing diagnosis. The symptoms of AML can easily be confused with symptoms of anaemia like malaise, easy fatigueability, low grade fever. Thrombocytopenia and anaemia are relatively common findings in pregnancy. Although, Neutropenia is rare and merits further investigation or close monitoring. But in the developing country like India, it is majorly missed. Thus, whenever there is presence of circulating blasts in a blood film, it suggests a diagnosis of haematological malignancy and is an indication for bone marrow biopsy. The other differential diagnosis that should be kept in mind are Thrombotic microangiopathy, HELLP syndrome and Cytopenias of deficiency or immune origin [2].

The tests to be done before bone marrow aspiration are Full blood count, blood film examination, Vitamin B12, folate and ferritin measurement, Coagulation screen, Renal and liver function tests. All these were done for our patient and further bone marrow aspiration was suggested with studies directed at Immunophenotypic, cytogenetic and molecular analysis for accurate subtyping and understanding of prognostic features.

Once diagnosed, a Multidisciplinary approach comprising of hematologists, obstetricians, anesthetists and neonatologists is the key to appropriate management. Consideration should be given to health of both mother and baby. The woman should be fully informed about the diagnosis, treatment of the disease and possible complications during pregnancy , clearly implying that any treatment delays might result in compromised maternal outcome without improving the outcome for the fetus [3].

The risks of Leukemia, disease per se, to pregnancy is miscarriage, foetal growth restriction, perinatal mortality, premature labour and Intrauterine fetal death [4].

Due to the high risk of the disease, there are different recommendations for management of AML in pregnancy in the three trimesters owing to the urgent need of chemotherapeutic agents and the adverse effects of the drugs involved .

If it is diagnosed in the first trimester, the patient should be counselled for elective abortion, medical/surgical and starting of chemotherapy. Between 13- 24 weeks, the Induction chemotherapy should be started while pregnancy is continued [5]. Preterm termination of pregnancy is indicated after fetal viability. Similar conclusions were derived by Nicola et al and Farhadfar in a single centre study of 5 and 23 case of AML diagnosed during pregnancy respectively [6,7].

Between 24 - 32 weeks, chemotherapy exposure to the fetus must be balanced against risks of prematurity following elective delivery at that stage of gestation (Grade 1C). At gestation age more than 32 weeks, the fetus should be delivered prior to Induction chemotherapy.

Chemotherapy with anthracycline based regimens are favored. According to a meta-analysis done by Natanel A Horowitz et al, anthracycline based regimens were associated with maximum remission but overall maternal survival was very low (30%)[8]. Even in our case, although the mother immediately had remission with chemotherapy. There was a recurrence after disease free 10 months and she succumbed to the disease during the COVID pandemic. Quinolones, tetracyclines and sulphonamides are better avoided in pregnancy(Grade 1B).

In one case report by Abdullah et al, a trial of 5- azacytidine has shown promising results [9]. The antifungal of choice in pregnancy is Amphotericin B or lipid derivatives (Grade 2C). If blood transfusion is needed, the blood should be screened for Cytomegalovirus (Grade 1B). Supportive therapy like a course of Corticosteroids given if delivery is between 24 and 35 weeks gestation (Grade 1A) [10]. Magnesium sulphate should be considered 24 h prior to delivery before 30 weeks gestation (Grade 1A).

Delivery should be planned for a time when the woman is at least 3 weeks post-chemotherapy to minimize risk of neonatal myelosuppresion (Grade 1C). Planned delivery is preferred, like Induction of labour (Grade 2C). Caesarean section is indicated only for obstetric indications. Epidural analgesia is better avoided.

The Dose of chemotherapy is calculated on their actual body weight with dose adjustments for weight gain during pregnancy owing to various pregnancy changes.

The Chemotherapy agents have a MW of 250-400 KDa and hence can cross the placenta resulting in detrimental teratogenic effects on developing fetus.Sunny J. Patel et al have done a comprehensive analysis on outcomes in hospitalized pregnant patients with acute myeloid leukemia and come to conclusion that a multidesciplinary, holistic approach leads to quick remission of the disease [11]

After delivery, histopathologic examination of placenta to rule out placental transfer to fetus is advisable. Cytologic examination should be performed in both maternal and umbilical cord blood and neonates should be clinically examined for palpable skin lesions, organomegaly or other masses. If the baby is found to be healthy, a follow up after every six months for two years is recommended. In each visit, physical examination, chest x-ray and liver function tests should be done.

Conclusion

Acute myeloid leukemia in pregnancy is a Rare diagnosis and even rarely reported. With the trend for delaying pregnancy into the later reproductive years, we expect to see more cases of cancer complicating pregnancy. Presently, there are no clear management guidelines to address timing and dosing of anthracycline/cytarabine based regimens especially in pregnancy. The potential drug toxicity to mother and fetus and transplant considerations in intermediate and highrisk patients during pregnancy has not been addressed.

What we also need today is a National registry for leukemia patients, treated in pregnancy. This will help us to answer many unanswered queries and improve maternal and fetal overall survival rates. Although we have few comprehensive studies, but further studies and references are needed. Finally, a Multidisciplinary team is needed to provide comprehensive care to patients.

[kirstythejetblackgoldfish]

[jppres]

Anti-leukemic activity of Cyperus rotundus L.on human acute myeloid leukemia HL-60 cells in vitro

Image: Flickr Article published in J. Pharm. Pharmacogn. Res., vol. 11, no. 1, pp. 191-197, January-February 2023. DOI: https://doi.org/10.56499/jppres22.1502_11.1.191 Sulistyo Mulyo Agustini1, Edi Widjajanto2, Muhaimin Rifa’i3, Sofia Mubarika Haryana4, Nurdiana5, Diana Lyrawati5, Usi Sukorini6, Noviana Dwi Lestari7* 1Department of Pathology, Faculty of Medicine, Muhammadiyah Malang…

[drpawankumarsingh]

How is Acute Myeloid Leukemia Diagnosed?

Acute myeloid leukemia is diagnosed through a series of tests. Doctors first do a blood test to check for abnormal cells. If the results are suspicious, they perform a bone marrow biopsy, where a small sample of bone marrow is taken and examined. Other tests like genetic studies might be done to understand the specific type of leukemia. Acute Myeloid Leukemia Specialists use these tests to make an accurate diagnosis and plan the best treatment.

[patchesthenerd]

Hi, I don't usually make my own posts. I mainly re log stuff, but I had to share this to hopefully get some more eyes on it. I understand that everyone is going through stuff these days, but if anyone's able to help, even just getting the word out, that would be much appreciated.

A friend of own of my closest friends is going through Leukemia and has to look into options that aren't covered by insurance anymore.

https://gofund.me/9c47ed3a

Again thank you in advance to any help that you might be able to provide.

[mecolin50]

THANKFUL & HOPEFUL

In the Spring March 1st  of 2023, my life took an unexpected turn when I was diagnosed with Acute Myeloid Leukemia (AML). The news was crushing, but little did I know that the National Health Service (NHS) would become my beacon of hope, pulling me from the jaws of certain death.

The early days were a whirlwind of tests, consultations, and preparations for treatment. The NHS staff worked tirelessly to ensure that every aspect of my care was meticulously planned. Their expertise and dedication were palpable, offering me not only medical support but also a glimmer of optimism in the face of adversity.

As I embarked on chemotherapy, the NHS stood as a formidable fortress between life and death. The precision and care with which the treatment was administered were awe-inspiring. The nurses, the unsung heroes of healthcare, became my pillars of strength. They navigated the delicate balance between compassion and professionalism with grace, offering comfort during my weakest moments.

After months of grueling treatment, the prospect of a bone marrow transplant emerged as my best chance for survival. The NHS orchestrated a symphony of coordination to find a suitable donor, a feat that could not be underestimated. The logistical challenges were immense, yet the NHS team tackled them head-on, leaving no stone unturned in their quest to save my life.

[stomeranclels451]

https://demo.sngine.com/blogs/173909/Dental-Amalgam-Market-Players-Overview-and-Growth-Prospects-by-2030

Acute Myeloid Leukemia Treatment Market Share, Growth Factors and Forecast to 2030

[heepthecheep]

I hate so much about how hematological diseases/conditions are named...

[bpod-bpod]

Blast Zone

An aggressive blood cancer, acute myeloid leukaemia (AML) occurs when abnormal developing white blood cells, known as blasts, start to multiply rapidly, filling up the bone marrow and disrupting the development of other blood cells. Pictured here are blasts (in purple) surrounded by red blood cells, from the bone marrow of a patient with Down syndrome; children with Down’s, a genetic condition caused by carrying a third copy of chromosome 21, are at much greater risk of developing AML. To understand why, researchers used gene editing tools to investigate all 218 genes on this extra chromosome. They homed in on RUNX1, which encodes a transcription factor, a protein that regulates other genes. RUNX1 can be expressed in several forms, and balance between them is key: these recent experiments suggest that AML is linked to an excess of a form called RUNX1A, opening up new avenues for research into potential treatments.

Written by Emmanuelle Briolat

Image by Jan Klusmann, University Hospital Frankfurt

Department of Pediatrics, Goethe University Frankfurt, Frankfurt am Main, Germany

Image copyright held by the original authors

Research published in Blood, March 2023

You can also follow BPoD on Instagram, Twitter and Facebook

[kirstythejetblackgoldfish]

Syrian First Lady Asma al-Assad has been diagnosed with acute leukaemia

Today, a video was posted where Asma thanked people for their heartfelt messages and how it has helped her family. She then spoke about how she is going into isolation for treatment, which means being away from her loved ones. She also said that she will fight this battle with full faith in God and with people's love and prayers

Asma was sitting behind a family photo, which was taken in Aleppo in July 2022

[marketsndata]

[kenresearch1]

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy.  The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.